The new MASCC/ESMO Guideline appears in a supplement to the September 2016 issue of Annals of Oncology* and is available for free download.
The guideline represents an update of the 2010 version and is based on the 2015 Copenhagen Consensus Conference with respect to the classification of the emetogenic potential of antineoplastic agents. The update adds 42 new drugs, many of which are orally administered. The full-text versions of the 2016 MASCC/ESMO Consensus Recommendation papers from Supportive Care in Cancer (27, Suppl. 5, 2016), which reflect the conclusions of the 2015 Consensus Conference, are available, courtesy of MASCC and Springer.
__________________________________
*Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol, 2016 Sep;27(suppl 5):v119-v133.
